Pinnacle Biologics, Inc., a subsidiary of Concordia Healthcare Corp., announces European site initiation of Phase 3 bile duct cancer trial using photodynamic therapy with PHOTOFRIN , a subsidiary of Concordia Healthcare Corp., , announced today the initiation of the pivotal Phase 3 trial in for a rare form of bile duct cancer for which there is currently no acceptable therapy. OPUS is an O pen-label, multicenter phase 3 on the efficacy and safety of P hotodynamic therapy with PHOTOFRIN for injection as treatment for U nresectable advanced perihilar cholangiocarcinoma Bismuth type III/IV S tudy.
